Table 1.
Selection criteria in different centers for hepatocellular carcinoma beyond the Milan criteria
| Criteria | Year | Country |
Sample size |
Contents of criteria |
Survival (5-yr) |
||
| DDLT | LDLT | OS | RFS | ||||
| UCSF[7] | 2001 | America | 70 | 0 | Tumor ≤ 6.5 cm, or ≤ 3 nodules with the largest ≤ 4.5 cm and a total tumor ≤ 8 cm | 75.2% | None |
| Up-to-7[8] | 2009 | Italy | 1404 | 121 | The sum of the tumor number and the size of the largest tumor no larger than 7 cm | 71.2% | None |
| Tokyo[9] | 2007 | Japan | 0 | 78 | Tumors no larger than 5 cm and no more than 5 nodules | 75.0% | 94% (3-yr) |
| Hangzhou[12] | 2008 | China | 195 | 0 | Tumor ≤ 8 cm, or tumor > 8 cm, histopathologic grade I or II and preoperative AFP ≤ 400 ng/mL | 78.3% | 62.4% |
| Kyoto[6] | 2007 | Japan | 0 | 125 | Tumor ≤ 10 nodules, all ≤ 5 cm and a serum DCP level ≤ 400 mAU/mL | 86.7% | None |
| Shanghai[14] | 2009 | China | 1074 | 4 | Tumor ≤ 9 cm, or ≤ 3 lesions with the largest ≤ 5 cm, tumor ≤ 9 cm without macrovascular and lymph node invasion and extrahepatic metastasis | 78.1% | 52.6% |
| Asan[11] | 2008 | South Korea | 0 | 221 | Tumor ≤ 5 cm in diameter, ≤ 6 in nodule number, and free of gross vascular invasion | 81.6% | None |
UCSF: University Of California San Francisco; LDLT: Living donor liver transplantation; DDLT: Deceased donor liver transplantation; OS: Overall survival; RFS: Relapse free survival.